A Man With Spinal Muscular Atrophy is Stuck Without Access to Costly Treatment
https://pixabay.com/en/clock-time-watch-hours-minutes-407101/

A Man With Spinal Muscular Atrophy is Stuck Without Access to Costly Treatment

According to a story from cbc.ca, Cole Pringle is a 31-year-old man from Regina, Saskatchewan with spinal muscular atrophy, a debilitating illness that severely affects his mobility. He was diagnosed…

Continue Reading A Man With Spinal Muscular Atrophy is Stuck Without Access to Costly Treatment
Researchers are Investigating the Link Between Circadian Rhythms and Spinal Muscular Atrophy
Alexas_Fotos / Pixabay

Researchers are Investigating the Link Between Circadian Rhythms and Spinal Muscular Atrophy

A recent study has found that ‘clock’ genes that help to regulate the body’s circadian rhythm may be affected by spinal muscular atrophy. The original paper, which is published in…

Continue Reading Researchers are Investigating the Link Between Circadian Rhythms and Spinal Muscular Atrophy
Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced
rawpixel / Pixabay

Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced

Data from a Phase II clinical trial of the experimental treatment reldesemtiv for the treatment of spinal muscular atrophy has been announced. The drug has shown positive effects in the…

Continue Reading Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced

Cure SMA’s Annual SMA Conference

  • Post author:
  • Post category:

The 2018 Annual SMA Conference This conference will bring together researchers, medical experts, scientists, and patient families to build community, learn, collaborate, and network. The conference consists of two parallel…

Continue Reading Cure SMA’s Annual SMA Conference
ICYMI: Experimental Drug for Spinal Muscular Atrophy Gets Orphan Drug Designation
source: pixabay.com

ICYMI: Experimental Drug for Spinal Muscular Atrophy Gets Orphan Drug Designation

According to a story from BioSpace, the pharmaceutical company Scholar Rock recently announced that its drug candidate SRK-015 was recently granted Orphan Drug Designation by the U.S. FDA. The drug…

Continue Reading ICYMI: Experimental Drug for Spinal Muscular Atrophy Gets Orphan Drug Designation
Australian Boy With Spinal Muscular Atrophy is Now Able to Get Critical Treatment
https://pixabay.com/en/autumn-fall-baby-boy-child-cute-275920/

Australian Boy With Spinal Muscular Atrophy is Now Able to Get Critical Treatment

According to a story from the Sydney Morning Herald, two-year-old William McLennan, son of Naomi Taylor and Ben McLennan, was diagnosed with spinal muscular atrophy about a year ago. The…

Continue Reading Australian Boy With Spinal Muscular Atrophy is Now Able to Get Critical Treatment
Parents of Kids With Spinal Muscular Atrophy Are Worried About Signing Them up for Clinical Trials
Source: Pixabay

Parents of Kids With Spinal Muscular Atrophy Are Worried About Signing Them up for Clinical Trials

According to a story from SMA News Today, a recent study has demonstrated that the parents of children with spinal muscular atrophy are often skeptical about enrolling their kids in…

Continue Reading Parents of Kids With Spinal Muscular Atrophy Are Worried About Signing Them up for Clinical Trials
Angelman Syndrome Treatment Being Developed is Awarded ‘Orphan Drug’ Status in the U.S.
Source: Pixabay

Angelman Syndrome Treatment Being Developed is Awarded ‘Orphan Drug’ Status in the U.S.

A new drug being developed to treat Angelman syndrome (AS) has just been approved for ‘orphan drug’ status in the U.S., reports GlobeNewswire. The drug, called GTX-101, works by activating the…

Continue Reading Angelman Syndrome Treatment Being Developed is Awarded ‘Orphan Drug’ Status in the U.S.
Investigational Gene Therapy for Spinal Muscular Atrophy Gets SAKIGAKE Designation
source: pixabay.com

Investigational Gene Therapy for Spinal Muscular Atrophy Gets SAKIGAKE Designation

According to a story from GlobeNewswire, The pharmaceutical company AveXis, Inc., a company that specializes in the development of gene therapies, recently announced that its candidate AVXS-101 was awarded SAKIGAKE…

Continue Reading Investigational Gene Therapy for Spinal Muscular Atrophy Gets SAKIGAKE Designation
Clinic Beats Slow Hospitals to be the First to Deliver Spinal Muscular Atrophy Drug in Michigan
source: pixabay.com

Clinic Beats Slow Hospitals to be the First to Deliver Spinal Muscular Atrophy Drug in Michigan

The day after Christmas in 2016 brought a post-Holiday surprise to many in the U.S. with spinal muscular atrophy. December 26, 2016 marked the day that Spinraza was approved by…

Continue Reading Clinic Beats Slow Hospitals to be the First to Deliver Spinal Muscular Atrophy Drug in Michigan
Spinraza, a New Drug For SMA Patients Might Be Available Sooner Than Later in the UK
Source: Pixabay

Spinraza, a New Drug For SMA Patients Might Be Available Sooner Than Later in the UK

There is new hope for patients and their families suffering from spinal muscular atrophy (SMA) reported AOL UK News. SMA is a physically debilitating and aggressive disease, and now a new…

Continue Reading Spinraza, a New Drug For SMA Patients Might Be Available Sooner Than Later in the UK